Novartis/HGS’ Albuferon ACHIEVEs Non-inferiority To Pegasys For Hepatitis C

Question now is whether the long-acting version of interferon will be able to make a “me-better” case based on dosing and quality of life benefits.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet